Skip to main content

Peer Review reports

From: Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Original Submission
13 Dec 2022 Submitted Original manuscript
31 Jan 2023 Reviewed Reviewer Report
8 Feb 2023 Reviewed Reviewer Report
23 Feb 2023 Author responded Author comments - Li Cai
Resubmission - Version 2
23 Feb 2023 Submitted Manuscript version 2
14 Mar 2023 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
24 Mar 2023 Editorially accepted
19 May 2023 Article published 10.1186/s12885-023-10768-8

You can find further information about peer review here.

Back to article page